The global immune-nutrition-inflammation index (GINI) as a robust prognostic factor in glioblastoma patients treated with the standard stupp protocol
Background Systemic inflammation can significantly impact gliomas’ onset, progression, and prognosis. Glioblastoma multiforme (GBM) represents the glioma subtype characterized by the most profound inflammatory and immunosuppressive states. Consequently, various blood-borne biomarkers have been scrut...
Gespeichert in:
| Veröffentlicht in: | International journal of immunopathology and pharmacology 2024-01, Vol.38, p.3946320241284089 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | 3946320241284089 |
| container_title | International journal of immunopathology and pharmacology |
| container_volume | 38 |
| creator | Topkan, Erkan Kilic Durankus, Nilufer Senyurek, Sukran Öztürk, Duriye Besen, Ali Ayberk Mertsoylu, Huseyin Pehlivan, Berrin Selek, Ugur |
| description | Background
Systemic inflammation can significantly impact gliomas’ onset, progression, and prognosis. Glioblastoma multiforme (GBM) represents the glioma subtype characterized by the most profound inflammatory and immunosuppressive states. Consequently, various blood-borne biomarkers have been scrutinized concerning their prognostic value in GBM patients.
Objective
We sought to investigate whether the recently introduced Global Immune-Nutrition-Inflammation Index (GINI) holds prognostic significance for GBM patients treated with the standard Stupp protocol.
Methods
We retrospectively analyzed the data from a cohort of newly diagnosed GBM patients receiving the standard Stupp regimen using the propensity score-matching methodology. The GINI was computed using the original formula: GINI = [(C-reactive protein × Monocytes × Platelets × Neutrophils) ÷ (Albumin × Lymphocytes)]. We employed receiver operating characteristic (ROC) curve analysis to identify the optimal cutoff values for GINI, which could help distinguish between different survival outcomes. The primary and secondary objectives were the differences in overall survival (OS) and progression-free survival (PFS) between the GINI groups.
Results
The optimal GINI cutoff value was 1350. Out of 294 eligible patients, 211 were PSM-matched: GINI |
| doi_str_mv | 10.1177/03946320241284089 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11440555</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_03946320241284089</sage_id><sourcerecordid>3149771111</sourcerecordid><originalsourceid>FETCH-LOGICAL-c306t-c09b710e7839e793d7d461db1e80bde19541690969fe0ba828176d31ab90a7aa3</originalsourceid><addsrcrecordid>eNp1kc1u1DAQgC0EoqvSB-CCLHEph5Rx7MT2CaEKykoVXMo5msTOrqvEDrbDz4Pwvni1pfwJX2xrvvlmRkPIUwYXjEn5ErgWLa-hFqxWApR-QDY1NKqSXImHZHOIVwfghJyldAsADLhoFHtMTrjm0AC0G_L9Zm_pbgo9TtTN8-pt5dccXXbBV86PE84zHj7UeWO_0vOr7fvtC4qJIo2hX1OmSww7H1J2Ax1xyCEWtChd6CdMOcxIl2KwPieao8VsDf3i8p7mUjll9AajKY91WQ6qHIYwPSGPRpySPbu7T8nHt29uLt9V1x-utpevr6uBQ5urAXQvGVipuLZScyONaJnpmVXQG8t0I1irQbd6tNCjqhWTreEMew0oEfkpeXX0Lms_WzOUJiNO3RLdjPFbF9B1f0a823e78LljTAhomqYYzu8MMXxabcrd7NJgpwm9DWvqOAMpVQMKCvr8L_Q2rNGX-QoltJSsnEKxIzXEkFK04303DLrD4rt_Fl9ynv0-xn3GzzUX4OIIJNzZX2X_b_wBo-m4Gg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3149771111</pqid></control><display><type>article</type><title>The global immune-nutrition-inflammation index (GINI) as a robust prognostic factor in glioblastoma patients treated with the standard stupp protocol</title><source>MEDLINE</source><source>Sage Journals GOLD Open Access 2024</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Topkan, Erkan ; Kilic Durankus, Nilufer ; Senyurek, Sukran ; Öztürk, Duriye ; Besen, Ali Ayberk ; Mertsoylu, Huseyin ; Pehlivan, Berrin ; Selek, Ugur</creator><creatorcontrib>Topkan, Erkan ; Kilic Durankus, Nilufer ; Senyurek, Sukran ; Öztürk, Duriye ; Besen, Ali Ayberk ; Mertsoylu, Huseyin ; Pehlivan, Berrin ; Selek, Ugur</creatorcontrib><description>Background
Systemic inflammation can significantly impact gliomas’ onset, progression, and prognosis. Glioblastoma multiforme (GBM) represents the glioma subtype characterized by the most profound inflammatory and immunosuppressive states. Consequently, various blood-borne biomarkers have been scrutinized concerning their prognostic value in GBM patients.
Objective
We sought to investigate whether the recently introduced Global Immune-Nutrition-Inflammation Index (GINI) holds prognostic significance for GBM patients treated with the standard Stupp protocol.
Methods
We retrospectively analyzed the data from a cohort of newly diagnosed GBM patients receiving the standard Stupp regimen using the propensity score-matching methodology. The GINI was computed using the original formula: GINI = [(C-reactive protein × Monocytes × Platelets × Neutrophils) ÷ (Albumin × Lymphocytes)]. We employed receiver operating characteristic (ROC) curve analysis to identify the optimal cutoff values for GINI, which could help distinguish between different survival outcomes. The primary and secondary objectives were the differences in overall survival (OS) and progression-free survival (PFS) between the GINI groups.
Results
The optimal GINI cutoff value was 1350. Out of 294 eligible patients, 211 were PSM-matched: GINI<1350 (N = 95) and GINI≥1350 (N = 116). Comparative Kaplan-Meier estimates indicated that the GINI≥1350 patients had substantially worse median PFS (8.0 vs 16.8 months; p < .001) and OS (14.3 vs 22.9 months; p < .001) durations than their GINI<1350 counterparts.
Conclusion
High pretreatment GINI values are robustly and independently associated with inferior PFS and OS outcomes in selected GBM patients who receive standard Stupp protocol. These findings suggest that if further confirmed, the novel GINI could serve as a valuable biological marker for the prognostic stratification of GBM patients.</description><identifier>ISSN: 0394-6320</identifier><identifier>ISSN: 2058-7384</identifier><identifier>EISSN: 2058-7384</identifier><identifier>DOI: 10.1177/03946320241284089</identifier><identifier>PMID: 39305006</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Brain Neoplasms - blood ; Brain Neoplasms - immunology ; Brain Neoplasms - mortality ; C-reactive protein ; C-Reactive Protein - analysis ; C-Reactive Protein - metabolism ; Female ; Glioblastoma ; Glioblastoma - blood ; Glioblastoma - immunology ; Glioblastoma - mortality ; Glioma ; Humans ; Inflammation ; Inflammation - immunology ; Leukocytes (neutrophilic) ; Lymphocytes ; Male ; Medical prognosis ; Middle Aged ; Monocytes ; Neutrophils - immunology ; Nutritional Status ; Original ; Prednisone - administration & dosage ; Prednisone - therapeutic use ; Prognosis ; Progression-Free Survival ; Retrospective Studies</subject><ispartof>International journal of immunopathology and pharmacology, 2024-01, Vol.38, p.3946320241284089</ispartof><rights>The Author(s) 2024</rights><rights>The Author(s) 2024. This work is licensed under the Creative Commons Attribution – Non-Commercial License https://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>The Author(s) 2024 2024 SAGE Publications Ltd unless otherwise noted. Manuscript content on this site is licensed under Creative Commons Licenses</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c306t-c09b710e7839e793d7d461db1e80bde19541690969fe0ba828176d31ab90a7aa3</cites><orcidid>0000-0002-3265-2797 ; 0000-0001-8120-7123</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440555/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC11440555/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,21945,27830,27901,27902,44921,45309,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39305006$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Topkan, Erkan</creatorcontrib><creatorcontrib>Kilic Durankus, Nilufer</creatorcontrib><creatorcontrib>Senyurek, Sukran</creatorcontrib><creatorcontrib>Öztürk, Duriye</creatorcontrib><creatorcontrib>Besen, Ali Ayberk</creatorcontrib><creatorcontrib>Mertsoylu, Huseyin</creatorcontrib><creatorcontrib>Pehlivan, Berrin</creatorcontrib><creatorcontrib>Selek, Ugur</creatorcontrib><title>The global immune-nutrition-inflammation index (GINI) as a robust prognostic factor in glioblastoma patients treated with the standard stupp protocol</title><title>International journal of immunopathology and pharmacology</title><addtitle>Int J Immunopathol Pharmacol</addtitle><description>Background
Systemic inflammation can significantly impact gliomas’ onset, progression, and prognosis. Glioblastoma multiforme (GBM) represents the glioma subtype characterized by the most profound inflammatory and immunosuppressive states. Consequently, various blood-borne biomarkers have been scrutinized concerning their prognostic value in GBM patients.
Objective
We sought to investigate whether the recently introduced Global Immune-Nutrition-Inflammation Index (GINI) holds prognostic significance for GBM patients treated with the standard Stupp protocol.
Methods
We retrospectively analyzed the data from a cohort of newly diagnosed GBM patients receiving the standard Stupp regimen using the propensity score-matching methodology. The GINI was computed using the original formula: GINI = [(C-reactive protein × Monocytes × Platelets × Neutrophils) ÷ (Albumin × Lymphocytes)]. We employed receiver operating characteristic (ROC) curve analysis to identify the optimal cutoff values for GINI, which could help distinguish between different survival outcomes. The primary and secondary objectives were the differences in overall survival (OS) and progression-free survival (PFS) between the GINI groups.
Results
The optimal GINI cutoff value was 1350. Out of 294 eligible patients, 211 were PSM-matched: GINI<1350 (N = 95) and GINI≥1350 (N = 116). Comparative Kaplan-Meier estimates indicated that the GINI≥1350 patients had substantially worse median PFS (8.0 vs 16.8 months; p < .001) and OS (14.3 vs 22.9 months; p < .001) durations than their GINI<1350 counterparts.
Conclusion
High pretreatment GINI values are robustly and independently associated with inferior PFS and OS outcomes in selected GBM patients who receive standard Stupp protocol. These findings suggest that if further confirmed, the novel GINI could serve as a valuable biological marker for the prognostic stratification of GBM patients.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Brain Neoplasms - blood</subject><subject>Brain Neoplasms - immunology</subject><subject>Brain Neoplasms - mortality</subject><subject>C-reactive protein</subject><subject>C-Reactive Protein - analysis</subject><subject>C-Reactive Protein - metabolism</subject><subject>Female</subject><subject>Glioblastoma</subject><subject>Glioblastoma - blood</subject><subject>Glioblastoma - immunology</subject><subject>Glioblastoma - mortality</subject><subject>Glioma</subject><subject>Humans</subject><subject>Inflammation</subject><subject>Inflammation - immunology</subject><subject>Leukocytes (neutrophilic)</subject><subject>Lymphocytes</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Middle Aged</subject><subject>Monocytes</subject><subject>Neutrophils - immunology</subject><subject>Nutritional Status</subject><subject>Original</subject><subject>Prednisone - administration & dosage</subject><subject>Prednisone - therapeutic use</subject><subject>Prognosis</subject><subject>Progression-Free Survival</subject><subject>Retrospective Studies</subject><issn>0394-6320</issn><issn>2058-7384</issn><issn>2058-7384</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>AFRWT</sourceid><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNp1kc1u1DAQgC0EoqvSB-CCLHEph5Rx7MT2CaEKykoVXMo5msTOrqvEDrbDz4Pwvni1pfwJX2xrvvlmRkPIUwYXjEn5ErgWLa-hFqxWApR-QDY1NKqSXImHZHOIVwfghJyldAsADLhoFHtMTrjm0AC0G_L9Zm_pbgo9TtTN8-pt5dccXXbBV86PE84zHj7UeWO_0vOr7fvtC4qJIo2hX1OmSww7H1J2Ax1xyCEWtChd6CdMOcxIl2KwPieao8VsDf3i8p7mUjll9AajKY91WQ6qHIYwPSGPRpySPbu7T8nHt29uLt9V1x-utpevr6uBQ5urAXQvGVipuLZScyONaJnpmVXQG8t0I1irQbd6tNCjqhWTreEMew0oEfkpeXX0Lms_WzOUJiNO3RLdjPFbF9B1f0a823e78LljTAhomqYYzu8MMXxabcrd7NJgpwm9DWvqOAMpVQMKCvr8L_Q2rNGX-QoltJSsnEKxIzXEkFK04303DLrD4rt_Fl9ynv0-xn3GzzUX4OIIJNzZX2X_b_wBo-m4Gg</recordid><startdate>202401</startdate><enddate>202401</enddate><creator>Topkan, Erkan</creator><creator>Kilic Durankus, Nilufer</creator><creator>Senyurek, Sukran</creator><creator>Öztürk, Duriye</creator><creator>Besen, Ali Ayberk</creator><creator>Mertsoylu, Huseyin</creator><creator>Pehlivan, Berrin</creator><creator>Selek, Ugur</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>AFRWT</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-3265-2797</orcidid><orcidid>https://orcid.org/0000-0001-8120-7123</orcidid></search><sort><creationdate>202401</creationdate><title>The global immune-nutrition-inflammation index (GINI) as a robust prognostic factor in glioblastoma patients treated with the standard stupp protocol</title><author>Topkan, Erkan ; Kilic Durankus, Nilufer ; Senyurek, Sukran ; Öztürk, Duriye ; Besen, Ali Ayberk ; Mertsoylu, Huseyin ; Pehlivan, Berrin ; Selek, Ugur</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c306t-c09b710e7839e793d7d461db1e80bde19541690969fe0ba828176d31ab90a7aa3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Brain Neoplasms - blood</topic><topic>Brain Neoplasms - immunology</topic><topic>Brain Neoplasms - mortality</topic><topic>C-reactive protein</topic><topic>C-Reactive Protein - analysis</topic><topic>C-Reactive Protein - metabolism</topic><topic>Female</topic><topic>Glioblastoma</topic><topic>Glioblastoma - blood</topic><topic>Glioblastoma - immunology</topic><topic>Glioblastoma - mortality</topic><topic>Glioma</topic><topic>Humans</topic><topic>Inflammation</topic><topic>Inflammation - immunology</topic><topic>Leukocytes (neutrophilic)</topic><topic>Lymphocytes</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Middle Aged</topic><topic>Monocytes</topic><topic>Neutrophils - immunology</topic><topic>Nutritional Status</topic><topic>Original</topic><topic>Prednisone - administration & dosage</topic><topic>Prednisone - therapeutic use</topic><topic>Prognosis</topic><topic>Progression-Free Survival</topic><topic>Retrospective Studies</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Topkan, Erkan</creatorcontrib><creatorcontrib>Kilic Durankus, Nilufer</creatorcontrib><creatorcontrib>Senyurek, Sukran</creatorcontrib><creatorcontrib>Öztürk, Duriye</creatorcontrib><creatorcontrib>Besen, Ali Ayberk</creatorcontrib><creatorcontrib>Mertsoylu, Huseyin</creatorcontrib><creatorcontrib>Pehlivan, Berrin</creatorcontrib><creatorcontrib>Selek, Ugur</creatorcontrib><collection>Sage Journals GOLD Open Access 2024</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>International journal of immunopathology and pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Topkan, Erkan</au><au>Kilic Durankus, Nilufer</au><au>Senyurek, Sukran</au><au>Öztürk, Duriye</au><au>Besen, Ali Ayberk</au><au>Mertsoylu, Huseyin</au><au>Pehlivan, Berrin</au><au>Selek, Ugur</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The global immune-nutrition-inflammation index (GINI) as a robust prognostic factor in glioblastoma patients treated with the standard stupp protocol</atitle><jtitle>International journal of immunopathology and pharmacology</jtitle><addtitle>Int J Immunopathol Pharmacol</addtitle><date>2024-01</date><risdate>2024</risdate><volume>38</volume><spage>3946320241284089</spage><pages>3946320241284089-</pages><issn>0394-6320</issn><issn>2058-7384</issn><eissn>2058-7384</eissn><abstract>Background
Systemic inflammation can significantly impact gliomas’ onset, progression, and prognosis. Glioblastoma multiforme (GBM) represents the glioma subtype characterized by the most profound inflammatory and immunosuppressive states. Consequently, various blood-borne biomarkers have been scrutinized concerning their prognostic value in GBM patients.
Objective
We sought to investigate whether the recently introduced Global Immune-Nutrition-Inflammation Index (GINI) holds prognostic significance for GBM patients treated with the standard Stupp protocol.
Methods
We retrospectively analyzed the data from a cohort of newly diagnosed GBM patients receiving the standard Stupp regimen using the propensity score-matching methodology. The GINI was computed using the original formula: GINI = [(C-reactive protein × Monocytes × Platelets × Neutrophils) ÷ (Albumin × Lymphocytes)]. We employed receiver operating characteristic (ROC) curve analysis to identify the optimal cutoff values for GINI, which could help distinguish between different survival outcomes. The primary and secondary objectives were the differences in overall survival (OS) and progression-free survival (PFS) between the GINI groups.
Results
The optimal GINI cutoff value was 1350. Out of 294 eligible patients, 211 were PSM-matched: GINI<1350 (N = 95) and GINI≥1350 (N = 116). Comparative Kaplan-Meier estimates indicated that the GINI≥1350 patients had substantially worse median PFS (8.0 vs 16.8 months; p < .001) and OS (14.3 vs 22.9 months; p < .001) durations than their GINI<1350 counterparts.
Conclusion
High pretreatment GINI values are robustly and independently associated with inferior PFS and OS outcomes in selected GBM patients who receive standard Stupp protocol. These findings suggest that if further confirmed, the novel GINI could serve as a valuable biological marker for the prognostic stratification of GBM patients.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>39305006</pmid><doi>10.1177/03946320241284089</doi><orcidid>https://orcid.org/0000-0002-3265-2797</orcidid><orcidid>https://orcid.org/0000-0001-8120-7123</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0394-6320 |
| ispartof | International journal of immunopathology and pharmacology, 2024-01, Vol.38, p.3946320241284089 |
| issn | 0394-6320 2058-7384 2058-7384 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11440555 |
| source | MEDLINE; Sage Journals GOLD Open Access 2024; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central |
| subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Brain Neoplasms - blood Brain Neoplasms - immunology Brain Neoplasms - mortality C-reactive protein C-Reactive Protein - analysis C-Reactive Protein - metabolism Female Glioblastoma Glioblastoma - blood Glioblastoma - immunology Glioblastoma - mortality Glioma Humans Inflammation Inflammation - immunology Leukocytes (neutrophilic) Lymphocytes Male Medical prognosis Middle Aged Monocytes Neutrophils - immunology Nutritional Status Original Prednisone - administration & dosage Prednisone - therapeutic use Prognosis Progression-Free Survival Retrospective Studies |
| title | The global immune-nutrition-inflammation index (GINI) as a robust prognostic factor in glioblastoma patients treated with the standard stupp protocol |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T07%3A51%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20global%20immune-nutrition-inflammation%20index%20(GINI)%20as%20a%20robust%20prognostic%20factor%20in%20glioblastoma%20patients%20treated%20with%20the%20standard%20stupp%20protocol&rft.jtitle=International%20journal%20of%20immunopathology%20and%20pharmacology&rft.au=Topkan,%20Erkan&rft.date=2024-01&rft.volume=38&rft.spage=3946320241284089&rft.pages=3946320241284089-&rft.issn=0394-6320&rft.eissn=2058-7384&rft_id=info:doi/10.1177/03946320241284089&rft_dat=%3Cproquest_pubme%3E3149771111%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3149771111&rft_id=info:pmid/39305006&rft_sage_id=10.1177_03946320241284089&rfr_iscdi=true |